Physician profile
Michael Mcfadden
NPI 1437156189
$899.09
in general payments reported to CMS, 2019-2025
13 companies · $15.95 in 2025
The $15.95 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $68.41 · 2021: $73.62 · 2022: $195 · 2023: $68.23 · 2024: $74.96 · 2025: $15.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $507.30 | 2019-2024 | Senza |
| Boston Scientific Corporation | $90.04 | 2022 | |
| Djo, LLC | $71.77 | 2023-2024 | Cmf |
| Nalu Medical, INC. | $57.31 | 2022 | |
| Medtronic USA, INC. | $31.94 | 2019 | |
| Baxter Healthcare | $26.11 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $21.82 | 2022 | |
| Collegium Pharmaceutical, INC. | $20.63 | 2024 | Belbuca |
| Endo Pharmaceuticals INC. | $20.12 | 2023 | Xiaflex |
| Valinor Pharma, LLC | $15.95 | 2025 | Movantik |
| Ironshore Pharmaceuticals INC. | $12.67 | 2019 | |
| Vertos Medical, INC. | $12.19 | 2019 | |
| Medtronic, INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.